Introducing the Galleri multi-cancer early detection test

Galleri is a blood test that can detect 50+ cancer types and can be taken annually.1,2

Request your Galleri test
Already have an account? Log in

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

illustrated video poster of the Galleri test sitting on a table in an examination room with an anatomy poster on the wall behind it

Patient Story: Roger, Cancer Signal Detected with the Galleri test

Patient Story: Roger, Cancer Signal Detected with the Galleri test

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Who is eligible?

The Galleri Test valued at $949 is available at no cost to Active Carpenters, Early Retirees, and their eligible spouse aged 50 and older or aged 40-49 with elevated risk factors. Participants covered under the Carpenters’ Medicare Plan are not eligible for the Galleri test.

Active Carpenters & Early Retirees

  • Aged 50 years old or older 
  • Aged 40-49 with elevated risk factors
  • Not covered under the Carpenters’ Medicare Plan
  • 40-49 and at least one of the following risk factors:
    • Personal history of cancer (Galleri was studied in individuals at least three years post-cancer treatment)*
    • Current smoker or history of smoking
    • Obesity
    • Diabetes
    • Family history of cancer (first degree relative)
    • Hereditary genetic predisposition
    • Occupational exposures (e.g. burn pits, asbestos)
    • Environmental exposures (e.g. alcohol consumption, sun exposure)
    • Autoimmune chronic inflammatory conditions (e.g. IBD, asthma)
    • Non-autoimmune chronic inflammatory conditions (e.g. cirrhosis, chronic hepatitis B/C)
    • Immunodeficiencies (e.g. primary or viral, such as HIV or HPV)
    • Solid organ transplantation

*Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.

Please note that the Galleri test is not available for people who are currently pregnant or undergoing cancer treatment.

woman with brown hair wearing a tan sweater and gray pants smiling softly and sitting on a chair in her living room

Spouses

  • Aged 50 years old or older 
  • Aged 40-49 with elevated risk factors
  • Not covered under the Carpenters’ Medicare Plan
  • 40-49 and at least one of the following risk factors:
    • Personal history of cancer (Galleri was studied in individuals at least three years post-cancer treatment)*
    • Current smoker or history of smoking
    • Obesity
    • Diabetes
    • Family history of cancer (first degree relative)
    • Hereditary genetic predisposition
    • Occupational exposures (e.g. burn pits, asbestos)
    • Environmental exposures (e.g. alcohol consumption, sun exposure)
    • Autoimmune chronic inflammatory conditions (e.g. IBD, asthma)
    • Non-autoimmune chronic inflammatory conditions (e.g. cirrhosis, chronic hepatitis B/C)
    • Immunodeficiencies (e.g. primary or viral, such as HIV or HPV)
    • Solid organ transplantation

*Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.

Please note that the Galleri test is not available for people who are currently pregnant or undergoing cancer treatment.

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them
Already have an account? Log in

Limited data exists regarding the performance of the Galleri test in individuals <50 years of age.2,4,5

Galleri for EAS Carpenters Benefit Funds Program

The Galleri Test valued at $949 is available at no cost to Active Carpenters, Early Retirees, and their eligible spouse aged 50 and older or aged 40-49 with elevated risk factors. Participants covered under the Carpenters’ Medicare Plan are not eligible for the Galleri test.

To request a test, you will need an Access ID. Your Access ID is the first initial of your first name, your last name and your date of birth.

Example Patient's Access ID:
Patient First Name: John
Patient Last Name: Smith
Patient Date of Birth: 01/01/1950
Patient's Access ID: jsmith01011950

Note: If your last name has a hyphen, do not include the hyphen in your Access ID.

Eligible individuals can request the test once every 12 months from the time of blood draw.

Screen for more in 4 simple steps

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

It will take about 7 minutes to complete an online health questionnaire about your medical history. The Galleri test, by GRAIL, is available by prescription only. By requesting the test and completing the questionnaire, you’re requesting a prescription from Recuro Health, an independent telemedicine provider.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the Recuro Health telemedicine provider confirms your eligibility and prescribes the Galleri test, you will receive a notification via email and a collection kit in the mail. Visit Galleri.com/schedule to book your blood draw appointment at a GRAIL blood draw partner.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

Bring your test kit and Test Requisition Form (TRF) with you to the appointment. A trained technician will draw your blood sample and ship the kit to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

Recuro Health will contact you when your result is ready — about 2-3 weeks after your blood is received at the GRAIL lab.

Already have an account? Log in

What does the Galleri test result mean?


The Galleri test detected DNA fragments associated with cancer in your blood sample. About 1 out of every 100 test has a Cancer Signal Detected result.5

This result will also include a prediction of the issue type or organ associated with the cancer signal, called a Cancer SIgnal Origin (CSO). This provides direction to your doctor on the cancer’s origin and can help guide the next steps for diagnosis.2,8

In a clinical study, around 6 out of 10 people with a Cancer Signal Detected result were diagnosed with cancer after diagnostic testing.13* 

Cancer signal detected thumb
NEXT STEPS

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing. Such testing may include lab work or imagining ordered by your healthcare provider to confirm cancer. 

*Based on the first ~25,000 participants with 1 year of follow-up. 

The Galleri test did not detect DNA fragments associated with cancer in your blood sample. 

Nearly 99% of people who use the Galleri test will screen negative.5 

This result does not completely rule out the possibility of cancer. While the Galleri test is a powerful tool, it cannot detect a signal for all cancers and not all cancers can be detected in the blood. Some cancers shed little or no DNA into the bloodstream, making them unlikely to be detected through a blood test (e.g., brain, skin, and early-stage breast and prostate cancers).14 False positive and false negative results do occur. This result does not predict whether you will develop cancer in the future. 

Cancer signal not detected thumb
NEXT STEPS

Continue with any routine cancer screenings your healthcare provider recommends. Do not ignore cancer signs or symptoms if they occur, as this could lead to delayed diagnosis. 

Cancer can be unpredictable. The Galleri test can be taken as a simple blood test. Adding the Galleri test to an annual routine can improve your chance of finding cancer early.12

CancerNavigator

EAS Carpenters Benefit Funds partners with CancerNavigator to ensure that members with a positive signal on their Galleri test have the support they need for diagnostic testing and next steps. CancerNavigator's dedicated Oncology Nurse Navigators can answer questions members may have related to a suspected or confirmed diagnosis, and can provide education and guidance at every step. For any questions about cancer support services please call EAS Carpenters Benefit Funds' dedicated CancerNavigator support line at (267)-579−2717.

Cancer screening with Galleri can make a difference

Galleri looks for many deadly cancers before symptoms appear from a single blood draw and identifies a unique “fingerprint” of 50+ cancers, including many without a recommended screening available today.
  • Jackie

    Patient testimonial: Jackie

    Cancer Signal Detected

  • Cindy testimonial preview

    Patient testimonial: Cindy

    Cancer Signal Detected

  • Jonathan Testimonial Lyphoma

    Patient testimonial: Jonathan

    Cancer Signal Detected

  • Rich testimonials

    Patient testimonial: Rich

    Cancer Signal Detected

  • Mary patient vid

    Patient testimonial: Mary

    Cancer Signal Detected

  • Roger testimonial

    Patient testimonial: Roger

    Cancer Signal Detected

  • Valerie

    Patient testimonial: Valerie

    Cancer Signal Detected

  • Patient story video still closeup of Tami

    Patient testimonial: Tami

    No Cancer Signal Detected

  • patient story video still of Keith and his wife on a walk

    Patient testimonial: Keith

    No Cancer Signal Detected

  • Jennifer Testimonial poster

    Patient testimonial: Jennifer

    No Cancer Signal Detected

  • Rich S Taci

    Patient testimonial: Rich & Staci

    Cancer Signal Detected

  • Oncologist perspective

    Oncologist Perspectives

1 / 12

Frequently Asked Questions

The Galleri Test valued at $949 is available at no cost to Active Carpenters, Early Retirees, and their eligible spouse aged 50 and older or aged 40-49 with elevated risk factors. Participants covered under the Carpenters’ Medicare Plan are not eligible for the Galleri test.

To access the Galleri test as a covered benefit, you must request the test through this web page. 

When you request the test, an independent telemedicine healthcare provider will review your request and order it if appropriate. The test is available by prescription only.

The cost of the Galleri test, blood draw, and laboratory fees are all covered under this benefit.

An at-home or in-lab blood draw is included in the price of the test if scheduled with one of our partner labs. Find a time and location convenient for you.

When requesting the Galleri test you will need to provide an “Access ID” to confirm eligibility for the benefit. Your Access ID is the first initial of your first name, your last name and your date of birth.

Example Patient's Access ID:

Patient First Name: John
Patient Last Name: Smith
Patient Date of Birth: 01/01/1950
Patient's Access ID: jsmith01011950

Note: If your last name has a hyphen, do not include the hyphen in your Access ID.

[OPTION 1]

If you are not eligible for the benefit under the [CLIENT] program, you may be able to use pretax dollars in your flexible spending account (FSA) or health savings account (HSA) to pay for the Galleri test on Galleri.com. Check with your FSA or HSA administrator or insurance provider to determine eligibility.

[OPTION 2]

To cover your portion of the benefit cost, you may be able to use pretax dollars in your flexible spending account (FSA) or health savings account (HSA) to pay for the Galleri test. Check with your FSA or HSA administrator or insurance provider to determine eligibility.

GRAIL is a healthcare company focused on improving health by pioneering new technologies for early cancer detection. GRAIL is the company that manufactures the Galleri multi-cancer early detection test. You may receive information or communications from GRAIL or Galleri about your benefit or the Galleri test.

Recuro Health is a nationwide, independent, telemedicine care provider, supporting virtual physician consultations related to receiving the Galleri test. A Recuro Health physician will review your test request and order the test, if appropriate. A Recuro Health provider will also share your test result with you.

Under the EAS Carpenters Benefit Funds program, eligible individuals are able to complete the Galleri test every 12 months.

To access the Galleri test as a covered benefit, you must request the test through this web page. An independent telemedicine provider will review your request and order the test, if appropriate.

The Galleri test is provided at no cost to eligible individuals only when obtained through this authorized site.

The blood draw associated with the Galleri test must occur on a date you are covered under this benefit.

Individuals are responsible for the full cost of the test when obtained via any other means, such as a personal physician, or when the blood draw date of service occurs after the benefit coverage has ended.

Your individual Galleri test result is confidential and will not be shared. EAS Carpenters Benefit Funds only receives de-identified and aggregated information across all employees (e.g., how many tests have been requested).

Galleri is a multi-cancer early detection test that can be taken as a simple annual blood test and screens for many of the deadliest cancers, often before they become symptomatic.3,5 The Galleri test gives you more control when it comes to cancer. 

In a clinical study, the Galleri test was able to detect a signal shared by more than 50 types of cancer.3 See the list of cancer types study participants had when a cancer signal was detected.6

Watch a short video to learn more

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Cancers growing in the body shed DNA into the bloodstream.3,6,7 Although there are many types of cancer, the DNA fragments can act like a unique “fingerprint” of cancer. The Galleri test screens for many of the deadliest cancers, often before they become symptomatic, including those without recommended screening tests.1,3,5 When there is a Cancer Signal Detected result, a predicted Cancer Signal Origin8 will also be included to help your healthcare provider determine the next steps for diagnosis. 

Watch a short video to learn more

More than 1 in 3 people will develop cancer in their lifetime.9 People over the age of 50 have a 13 times higher risk for cancer than those under 50.10 Cancer risk increases for everyone as they age, regardless of family history10 — only 5% to 10% of cancers are inherited.10,11 

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. Talk to your provider about your risk for cancer and whether the Galleri test is right for you. 

Learn more about cancer risk

In a clinical study, the Galleri test detected a signal shared by over 50 types of cancer — including some fast-spreading and aggressive cancers responsible for approximately two-thirds of cancer deaths.3 Galleri is a cancer screening test, meaning it looks for cancer before symptoms appear.5 The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. 

See the list of cancer types study participants had when a cancer signal was detected.6 

False positive and false negative results do occur.

Nearly 99% of people who take the Galleri test will receive a No Cancer Signal Detected result. A Cancer Signal Detected result is expected in approximately 1% of Galleri tests in people over 50 years of age. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.5 

Some of the ways we measure test accuracy is with positive predictive value (PPV) and a false positive rate. A PPV is the probability that a person with a Cancer Signal Detected test result has cancer. In a recent study, the PPV was 43.1% for study participants with a Cancer Signal Detected result who were diagnosed with cancer.5 The false positive rate was 0.5% for participants without cancer.3,5

No, a genetic or hereditary risk assessment is a one-time-only measurement that assesses your future risk of developing cancer. The Galleri test is a point-in-time test that identifies DNA in the bloodstream shed by cancer cells and screens for cancer at the time of testing.

The test is only available in the US at this time.

Schedule a time and place convenient for you. Visit: Galleri.com/schedule to select either

  • A partner lab
  • A mobile phlebotomy option
    • A trained technician will come to your home, office, or any preferred location to complete your blood draw.

Learn more about how your sample is processed at the GRAIL laboratory by watching this video.

Once you receive your sample collection kit, please do not break the quality seal on it. The collection kit should be opened by the trained technician who draws your blood sample.

Store the kit at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, do not store the collection kit in a car.

To schedule your blood draw visit: Galleri.com/schedule 

The trained technician who draws your blood will pack and ship your sample back to the GRAIL laboratory for processing. Everything needed to complete the blood and return the sample is within the Galleri kit.

If you or your blood draw technician has questions, please call Customer Service: (833) 694‑2553.

No, fasting is not required for the Galleri test.

Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes from a vein in your arm.

If you no longer wish to receive your Galleri test result, contact GRAIL Customer Service by calling (833) 694‑2553.

Partner lab draw: Your sample will arrive at the lab 1-2 business days after your blood draw. Test results will be available about 2-3 weeks after your sample is received at the GRAIL lab.

On-site events: Your test result from the blood draw event will be delivered in 2-3 weeks. Your result will be communicated to you from the ordering provider at the event. Some samples may take more or less time to process so not all test results will be released on the same day. 

Your test result can be requested by contacting GRAIL Customer Service by calling (833) 694‑2553.

The Galleri test detected DNA methylation patterns that are often associated with cancer in your blood sample. About 1 out of every 100 tests has a Cancer Signal Detected result.5 

This result will also include a prediction of the tissue type or organ associated with the cancer signal, called a Cancer Signal Origin. This helps your doctor determine the next steps for diagnosis. 

Results should be interpreted by a healthcare provider. This test result is not a cancer diagnosis and requires follow-up diagnostic testing, which may include lab work or imaging ordered by your healthcare provider to confirm cancer. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps. 

False positive results do occur.

The Galleri test looked for a cancer signal in your blood sample and did not find one. This result does not completely rule out the possibility of cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Continue with routine cancer screenings your healthcare provider recommends. 

A Galleri test result of No Cancer Signal Detected does not rule out cancer.

The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests your healthcare provider recommends. Single-cancer screening tests are recommended because they have been proven to save lives by detecting cancer early. Using the Galleri test in addition to recommended single-cancer screenings can increase your chances of detecting cancer early, to allow for earlier treatment.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood.

A Cancer Signal Detected test result is not a cancer diagnosis. A Cancer Signal Detected result requires follow-up diagnostic testing, which may include lab work or imaging ordered by your healthcare provider. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.

All results are automatically shared with the provider who ordered the test. When requesting the test, you may provide the information for your primary care provider. If you would like us to fax your results to an additional healthcare provider, please contact Customer Service by calling (833) 694‑2553 to receive instructions on how to complete a test result release form.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes

  1. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screening [cited 2025 Mar 18]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
  2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
  3. American Cancer Society. Cancer facts & figures 2023. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html [GRAIL, Inc. Data on file: GA-2021-0065]
  4. Matrana M, Shukla V, Kingsbury D, et al. Real‑world data and clinical experience from over 100,000 multi‑cancer early detection tests [poster]. American Association for Cancer Research (AACR) Annual Meeting; 2025 Apr 25-30; Chicago. https://assets.grail.com/wp-content/uploads/2025/04/7202.Matrana.AACR-2025-RWE-100K_Poster_Final.pdf
  5. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-60. doi: 10.1016/S0140-6736(23)01700-2
  6. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-59. doi: 10.1016/j.annonc.2020.02.011
  7. Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35(3):347-76. doi: 10.1007/s10555-016-9629-x
  8. GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592] 
  9. American Cancer Society. Lifetime risk of developing or dying from cancer [cited 2025 Mar 11].  https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html
  10. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Regs, Nov 2020 Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, Surveillance Research Program, released Apr 2021, based on the Nov 2020 submission. [Risk factor data on file: American Cancer Society Cancer Prevention Studies II/III]
  11. American Cancer Society. Understanding genetic testing for cancer risk [cited 2024 Mar 15]. https://www.cancer.org/cancer/risk-prevention/genetics/genetic-testing-for-cancer-risk/understanding-genetic-testing-for-cancer.html 
  12. Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality. European Society for Medical Oncology (ESMO) Virtual Congress [poster]; 2021 Sep 16-21.
  13. Nabavizadeh N, et al. Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: initial results from the registrational PATHFINDER2 study [proffered presentation]. European Society for Medical Oncology (ESMO) Annual meeting: 2025 Oct 17-21; Berlin.
  14. Bredno J, Venn O, Chen X, et al. Circulating tumor DNA allele fraction: a candidate biological signal for multi-cancer early detection tests to assess the clinical significance of cancers. Am J Pathol. 2022; 192(10):1368-78. doi:10.1016/j.ajpath.2022.07.007